Form HLTH5819 Special Authority Request - Dapagliflozin for Heart Failure With Reduced Ejection Fraction (Hfref) is a document used in British Columbia, Canada to request special authorization for the use of the medication Dapagliflozin in the treatment of heart failure with reduced ejection fraction (HFREF).
In British Columbia, Canada, the form HLTH5819 Special Authority Request - Dapagliflozin for Heart Failure With Reduced Ejection Fraction (Hfref) is filed by healthcare providers on behalf of their patients.
Q: What is HLTH5819?
A: HLTH5819 is a special authority request form for Dapagliflozin in British Columbia, Canada.
Q: What is Dapagliflozin?
A: Dapagliflozin is a medication used for the treatment of heart failure with reduced ejection fraction (Hfref).
Q: Who can use Dapagliflozin?
A: Dapagliflozin is used for patients with heart failure and reduced ejection fraction (Hfref) in British Columbia, Canada.
Q: What is reduced ejection fraction (Hfref)?
A: Reduced ejection fraction (Hfref) is a condition where the heart does not pump blood effectively.
Q: How do I request special authority for Dapagliflozin?
A: You need to fill out the HLTH5819 special authority request form for Dapagliflozin in British Columbia, Canada.
Q: What is the purpose of the special authority request?
A: The purpose of the special authority request is to determine if the patient qualifies for coverage of Dapagliflozin.
Q: Is Dapagliflozin covered by insurance in British Columbia?
A: Coverage for Dapagliflozin can be determined through the special authority request process.
Q: Who can help me with the special authority request?
A: You can seek assistance from your healthcare provider or pharmacist with the special authority request.
Q: Are there any eligibility criteria for Dapagliflozin coverage?
A: Yes, there are eligibility criteria that need to be met for Dapagliflozin coverage in British Columbia, Canada.